Practitioner's Docket No. 47980 (1008)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ryncarz, Alexander J.

Serial No.: 08/791,240

Group No.: 1807

Filed:January 30, 1997

Examiner: Sisson, Bradley L.

For: Positive Controls in Polynucleotide Amplification

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1. [x] This replies to the Office Letter dated September 18, 1997

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

[x] A copy of the Office Letter is enclosed.

CERTIFICATION UNDER 37 CFR 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

[x] deposited with the United States Postal Service in an envelope addressed to the Assistant commissioner for Patents, Washington, D.C. 20231

37 CFR 1.8 (a)

37 CFR 1.10*

[] with sufficient postage as first class mail. [x] as "Express Mail Post Office to addressee" Mailing Label No. TB498181772US

(mandatory)

TRANSMISSION

[] transmitted by facsimile to the Patent and Trademark Office.

Date: //30/98

Signature

Robert L. Buchanan

Type or print name of person certifying)

*WARNING: Each paper or fee filed by Express Mail must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C. F. R. 1.10(b). "Since the filing of correspondence under §1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition. "Notice of Oct.24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Submission--Nucleotide and/or Amino Acid Sequence [9-37]--page 1 of 6)

IDENTIFICATION OF DECLARANT

I, Linda M. Buckley
 (type or print name of declarant signing below)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are

(check each item as applicable)


"Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in A. [x] this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823. An amendment to the description and/or claims, wherein reference is B. [x] made to the sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d). A copy of each "Sequence Listing" submitted for this application in computer C. [x] readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824. Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), D. the computer readable copy(ies) from applicant's other application identified as follows: In re application of: Serial No.: 1 Group No.: Examiner: Filed: For:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form "Sequence Identifier"

(other application) (this application)

(Submission--Nucleotide and/or Amino Acid Sequence [9-37]--page 2 of 6)



- E. [x] A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).
 - [] Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. § 1.821(b).
- F. [x] Because this submission is made in fulfilling the requirement under 37C.F.R. § 1.821(g), a statement that the submission includes no new matter.
 - [] Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. § 1.821(g).

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [x] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [x] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

VERIFICATION

- 5. NOTE: "Such a statement must be verified statement if made by a person not registered to practice before the Office." 37 C.F.R. § 1.821(f) and (g).
 - [] I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true: and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

STATUS

3.	Applicant is
]	a small entity. A verified statement: [] is attached. [] was already filed.

[x] other than a small entity.

(Submission-Nucleotide and/or Amino Acid Sequence [9-37]--page 3 of 6)

EXTENSION OF TERM

7.

[]

NOTE: "Extension of Time in Patent Cases (Supplement Amendments)-If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run. Notice of Dec.10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.

8. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b) as applicable)

(a) [x] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)-(d)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity	
[X] one month [] two months [] three months [] four months	\$ 110.00 \$ 400.00 \$ 950.00 \$ 1,510.00	\$ 55.00 \$ 200.00 \$ 475.00 \$ 755.00	

Fee

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

An extension for _____ months has already been secured. The fee paid therefor

	of \$ is deducted from the total fee due for the total months of extension now requested.
	Extension fee due with this request \$
	OR
(b)	[] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently

FEE PAYMENT

overlooked the need for a petition for extension of time.

9.	[] [X]	Attached is a check in the sum of \$ Charge Account No. 04-5010 the sum of \$	192.00	
	L. 3	A duplicate of this transmittal is attached.		

(Submission--Nucleotide and/or Amino Acid Sequence [9-37]--page 4 of 6)

10.

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked See the Notice of April 7, 1986, 1065 O.G. 31-33.

11. [x] If any additional extension and/or fee is required, charge Account No. 04-0010

SIGNATURE(s)

(Ē		la M. Bu me of pe	ckley erson signing declaration)	
	Signature Signature			
Dike, Bronstein, Roberts & 130 Water Street Boston, MA 02109 P.O. Address of Signatory				
(if applicable) Telephone No. (617) 523-3400 Reg. No. 31,003 Customer No.:			Inventor(s) Assignee of complete interest Person authorized to sign on behalf of assignee Practitioner of record Filed under Rule 34(a) Registration No. Other	
	(complete th	e follow	ing, if applicable)	
(type name of assignee)				
Address of assignee				

Title of person authorized to sign on behalf of assignee

A "CERTIFICATE UNDER 37 C.F.R. 3.73(b)" is attached.

(Submission--Nucleotide and/or Amino Acid Sequence [9-37]--page 5 of 6)

Assignment recorded in PTO on	
Reel Frame	
	SIGNATURE OF PRACTITIONER
Reg. No.:	
	(type or print name of practitioner)
Tel. No.: ()	
	(P.O. Address)
Customer No.:	

(Submission--Nucleotide and/or Amino Acid Sequence [9-37]--page 6 of 6)



Docket No.: 47980 (1008)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Ryncarz, Alexander J.

EXAMINER: Sisson, B.L.

SERIAL NO.: 08/791,240

GROUP: 1807

FILED: January 30, 1997

FOR: Positive Controls in Polynucleotide Amplification

CERTIFICATE OF MAILING

I hereby certify that this SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE (Transmittal), COPY OF COMMUNICATION DATED September 18, 1997, STATEMENTS IN SUPPORT OF FILING AND SUBMISSIONS IN ACCORDANCE WITH 37 CFR §§1.821-1.825, SEQUENCE LISTING COMPUTER PRINTOUT, 5-¼" FLOPPY DISK CONTAINING THE SEQUENCE LISTING, PRELIMINARY AMENDMENT, and SUBSTITUTE PAGES (Sheets 47-60) for the above-identified Application are being deposited with the United States Postal Service as express mail in an envelope addressed to BOX SEQUENCE, Commissioner of Patents and Trademarks, Washington, DC 20231, on this 30 th day of January, 1998.

Robert L. Buchanan

PAGE: 1

SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/08/791,240A

DATE: 09/18/97 TIME: 10:45:59

INPUT SET: S20410.raw

Line	Error	Original Text
132 132	Wrong Nucleic Acid Designator Wrong Nucleic Acid Designator	CGACTCACTA TAGGGCGAAT TGG*G*C CGACTCACTA TAGGGCGAAT TGG*G*C

BEST AVAILABLE COPY

PAGE: 3

RAW SEQUENCE LISTING PATENT APPLICATION US/08/791,240A

DATE: 09/18/97 TIME: 10:45:57

			INPUT S	ET: S20410.raw
	126		••	
	127	(B) STRAIN:		
	128			
	129			•
	130	(xi) SEQUENCE DESCRIPTION: SEQ_ID_NO: 2:	d 11/2 1	I La A signerie -
	131	a a invalid characters - h	or allow	
>	132	(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: CGACTCACTA TAGGGCGAAT TGGGCC	25	it's unclear what they request
	133	• •		// / / / /
	134			what they
	135			_ _
	136			regereen
	137			•
	138			

BEST AVAILABLE COPY.

RAW SEQUENCE LISTING PATENT APPLICATION US/08/791,240A

DATE: 09/18/97 TIME: 10:45:55

INPUT SET: S20410.raw

46		and the second second	. •		
47 48	(Vii)	PRIOR APPLICAT	יד אין די אי		
49	(\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	PRIOR APPLICAT	ION DATA:		
50	(A)	APPLICATION NU	MBER:		
51					
52	(B)	FILING DATE:			
53 54					
55	(viii)	ATTORNEY/AGENT	INFORMATION:		U
56				_	C C
57	(A)	NAME:	Jerome Rosenstoc	k, Esq.	max)
58 59	(B)	REGISTRATION N	IUMBER: 25,456		
60	(-/		20,00		
61	(C)	REFERENCE/DOCK	KET NUMBER: BDI-1020		
62 63	/i mere	COMMUNICATION 1	NEODWATTON.		
64	(IX) TELE	COMMONICATION	INFORMATION:		
65	(A)	TELEPHONE:	(908) 231-2125		AVAILABLE
66					
67 68	(B)	TELEFAX:	(908) 231-4919		\bigcirc
68 69					COP
.					

ERRORED SEQUENCES FOLLOW:

103	(2) INFORMATION FOR SEQ ID NO:2:
104	
105	(i) SEQUENCE CHARACTERISTICS:
106	
107	(A) LENGTH: 25 base pairs
108	
109	(B) TYPE: nucleic acid
110	
111	(C) STRANDEDNESS: single
112	
113	(D) TOPOLOGY: linear
114	
115	(ii) MOLECULE TYPE:
116	
117	(iii) HYPOTHETICAL: NO
118	
119	(iv) ANTI-SENSE: NO
120	
121	(v) FRAGMENT TYPE: C-terminal
122	
123	(vi) ORIGINAL SOURCE:
124	
125	(A) ORGANISM:

1

5 6

7 8

9 10

11 12 13

14 15

16 17

18

19

20 21

22 23

24 25

26

27 28

29 30 31

32

33 34 35

36

37 38

39 40

41 42

RAW SEQUENCE LISTING PATENT APPLICATION US/08/791,240A

DATE: 09/18/97 TIME: 10:45:53

Corrected Diskette Needed

INPUT SET: S20410.raw

This Raw Listing contains the General Information Section and those Sequences containing ERRORS.

SEQUENCE LISTING

.GE

BEST AVAILABLE COPY

2			
3	(1)	General	Information:

- (i) APPLICANT: Ryncarz, Alexander J.
- (ii) TITLE OF INVENTION: Positive Controls in Polynucleotide Amplification
- (iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Jerome Rosenstock, Esq.
- (B) STREET: Rt. 202-206 North/P.O. Box 2500
- (C) CITY: Somerville
- (D) STATE: New Jersey
- (E) COUNTRY: U.S.A.
- (F) ZIP: 08876-1258


(V) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
- (B) COMPUTER: DELL 486
- (C) OPERATING SYSTEM: WINDOWS 3.1
- (D) SOFTWARE: WORDPERFECT 6.0a

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: 08/798,240
- 43 (B) FILING DATE: January 30, 1997
- 44 45 (C) CLASSIFICATION:

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 8/79/240A

Art Unit / Team No.: /807

Date Processed by STIC: 9//8/97

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

ARTI SHAH 703-308-4212